RedHill Biopharma (RDHL)
NASDAQ:RDHL
Want to see RDHL full AI Analyst Report?
RDHL Stock Chart & Stats
$1.20
-$0.32(-4.91%)
At close: 4:00 PM EST
$1.20
-$0.32(-4.91%)
Day’s Range― - ―
52-Week Range$0.71 - $3.31
Previous CloseN/A
Volume5.64K
Average Volume (3M)1.98M
Market Cap
$5.40M
Enterprise Value$495.45K
Total Cash (Recent Filing)$2.87M
Total Debt (Recent Filing)$214.00K
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.00
Shares Outstanding5,191,260
10 Day Avg. Volume104,605
30 Day Avg. Volume1,981,143
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.76
Price to Sales (P/S)11.38
P/FCF Ratio-0.34
Enterprise Value/Market Cap0.09
Enterprise Value/Revenue0.05
Enterprise Value/Gross Profit0.08
Enterprise Value/Ebitda-0.06
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)$50.60M
Bulls Say, Bears Say
Bulls Say
Talicia Market PositionTalicia’s unique all‑in‑one positioning, guideline recognition and long patent/exclusivity runway provide a durable commercial asset. The Cumberland co‑commercialization reduces go‑to‑market risk and fixed sell‑through costs, supporting sustained prescription uptake and licensing upside over multiple years.
RHB-204 Next‑generation Crohn’s CandidateRHB‑204 builds on prior Phase‑3 evidence for RHB‑104 while promising lower doses and improved tolerability. Targeting a biomarker defined MAP‑positive Crohn’s population could enable clearer trial endpoints, partner interest and non‑dilutive funding, making this a structurally valuable pipeline asset.
Improved Leverage And SolvencyMaterial reduction in debt and a return to positive equity materially improve solvency versus recent years. This stronger balance sheet enhances the company’s ability to execute licenses, co‑commercial launches and targeted R&D investments without immediate forced restructurings, lowering near‑term refinancing risk.
Bears Say
Severe Revenue DeclineThe dramatic top‑line collapse erodes a stable revenue base and undermines internal cash generation. With product sales no longer reliably funding operations, management must depend on milestone/licensing receipts or external capital, making revenue sustainability and commercial traction uncertain.
Persistent Operating Cash BurnConsistently large negative operating cash flow indicates the business cannot self‑fund near‑term development or launches. This chronic burn creates structural dependence on external financing or asset monetization, increasing the likelihood of dilutive raises or constrained R&D and commercialization timelines.
Listing Risk And Dilution CapacityA Nasdaq deficiency notice elevates long‑term liquidity and financing risk; potential delisting would impair capital access. Coupled with approved share capital increases and RSU grants, management has ammunition for dilution to address the issue, which could erode shareholder value and limit strategic optionality.
RedHill Biopharma News
RDHL FAQ
What was RedHill Biopharma’s price range in the past 12 months?
RedHill Biopharma lowest stock price was $0.71 and its highest was $3.31 in the past 12 months.
What is RedHill Biopharma’s market cap?
RedHill Biopharma’s market cap is $5.40M.
When is RedHill Biopharma’s upcoming earnings report date?
RedHill Biopharma’s upcoming earnings report date is Aug 13, 2026 which is in 99 days.
How were RedHill Biopharma’s earnings last quarter?
Currently, no data Available
Is RedHill Biopharma overvalued?
According to Wall Street analysts RedHill Biopharma’s price is currently Overvalued.
Does RedHill Biopharma pay dividends?
RedHill Biopharma does not currently pay dividends.
What is RedHill Biopharma’s EPS estimate?
RedHill Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RedHill Biopharma have?
RedHill Biopharma has 5,191,260 shares outstanding.
What happened to RedHill Biopharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of RedHill Biopharma?
Currently, no hedge funds are holding shares in RDHL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RedHill Biopharma
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of innovative therapies for gastrointestinal diseases and cancer. The company operates primarily in the biopharmaceutical sector, with a strong emphasis on creating oral drug formulations that address unmet medical needs. RedHill's core products include therapies targeting conditions such as peptic ulcers, inflammatory bowel disease, and other gastrointestinal disorders, as well as oncology treatments.
Technical Analysis
China Pharma Holdings
―
Sonoma Pharmaceuticals
―
PainReform
―
Universe Pharmaceuticals
―
Shuttle Pharmaceuticals Holdings, Inc.
―
Ownership Overview
― Insiders
―
Mutual Funds
9.25% Other Institutional Investors
90.75% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---